FDA Reviewing Heart Side Effects of Invirase in Combo With Norvir

The FDA has announced that it is reviewing the possibility of dangerous heart side effects when the HIV drugs Invirase and Norvir are used together.

The Invirase safety review was announced on February 23, and the FDA reports that their preliminary findings indicate that when the two drugs are combined it could increase the risk of heart abnormalities leading to irregular heart rhythms. The abnormal heart rhythms, a condition called torsades de pointes, can cause fainting, lightheadedness and could leave to life-threatening irregular heart beats.

Invirase (saquinavir) is an antiretroviral medication manufactured by Genentech, which is a subsidiary or Roche AG. The drug was first approved in 1995. It is often used in combination with Abbott Laboratories’ Norvir (ritonavir), another antiretroviral drug approved by FDA in 1996.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Both drugs are classed as protease inhibitors, which prevent viral replication. Norvir is generally used specifically to boost Invirase’s abilities to combat the replication of HIV in the body.

FDA reviewers said that the current data suggests that using the two drugs together can affect the electrical activity of the heart, causing prolonged electrical signals called QT and PR intervals that can increase the risk for abnormal rhythms or even cause the heart beat to slow or stop, a condition known as a heart block.

The FDA is cautioning physicians to be aware of the possibility that the use of the two drugs can change electrical activity in the heart. The agency advises that neither drug should be given to patients who are already taking medications which have been identified as causing QT interval prolongation, including Class IA and Class III antiarrhythmic drugs. The drugs should also not be given to patients with a history of QT interval prolongation.

The FDA said that its investigation is ongoing, and the agency will update the public when the review is complete. Currently, the FDA is advising that patients should not stop taking the drugs without first consulting a health care professional.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.